Samsung Bioepis Inks Settlement and Licensing Deal with Regeneron for Commercialization of Opuviz (Biosimilar, Eylea) in the US 

Shots:  Samsung Bioepis has signed a settlement and license agreement with Regeneron for the commercialization of Opuviz, a biosimilar version of Eylea 2 mg, in the US, following an earlier settlement covering Europe and the Rest of the World (RoW)  Samsung Bioepis will launch Opuviz 2 mg in the US starting January 2027 under this agreement, with other terms remaining confidential  In May 2024, The US…